132 related articles for article (PubMed ID: 38151058)
41. Hyperandrogenemia association with acne and hirsutism severity in Croatian women with polycystic ovary syndrome.
Pavičić Baldani D; Škrgatić L; Bukvić Mokos Z; Trgovčić I
Acta Dermatovenerol Croat; 2013; 21(2):105-12. PubMed ID: 24001418
[TBL] [Abstract][Full Text] [Related]
42. The effect of hyperandrogenism and obesity on mindfulness and metacognition in adolescents with polycystic ovary syndrome.
Kara O; Kaymaz N; Uzun ME
Arch Womens Ment Health; 2022 Oct; 25(5):911-921. PubMed ID: 36074275
[TBL] [Abstract][Full Text] [Related]
43. Spironolactone as a single agent for long-term therapy of hirsute patients.
Spritzer PM; Lisboa KO; Mattiello S; Lhullier F
Clin Endocrinol (Oxf); 2000 May; 52(5):587-94. PubMed ID: 10792338
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of the pro-inflammatory cytokine tumor necrosis factor-α in adolescents with polycystic ovary syndrome.
Pawelczak M; Rosenthal J; Milla S; Liu YH; Shah B
J Pediatr Adolesc Gynecol; 2014 Dec; 27(6):356-9. PubMed ID: 25256873
[TBL] [Abstract][Full Text] [Related]
45. Endocrinological markers for assessing hyperandrogenemia in women classified as having polycystic ovary syndrome (PCOS) according to the revised 2003 diagnostic criteria.
Mueller A; Dittrich R; Binder H; Hoffmann I; Beckmann MW; Cupisti S
Eur J Med Res; 2006 Dec; 11(12):540-4. PubMed ID: 17182367
[TBL] [Abstract][Full Text] [Related]
46. CAG repeat polymorphism in androgen receptor gene is not directly associated with polycystic ovary syndrome but influences serum testosterone levels.
Skrgatic L; Baldani DP; Cerne JZ; Ferk P; Gersak K
J Steroid Biochem Mol Biol; 2012 Feb; 128(3-5):107-12. PubMed ID: 22107839
[TBL] [Abstract][Full Text] [Related]
47. Insulin sensitivity does not differentiate by hirsutism in non-obese women with polycystic ovary syndrome.
Cosar E; Koken G; Sahin FK; Arioz DT; Yilmazer M
Endocr J; 2008 Jul; 55(3):465-8. PubMed ID: 18520106
[TBL] [Abstract][Full Text] [Related]
48. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism.
Carmina E; Rosato F; Jannì A; Rizzo M; Longo RA
J Clin Endocrinol Metab; 2006 Jan; 91(1):2-6. PubMed ID: 16263820
[TBL] [Abstract][Full Text] [Related]
49. Association of ethnicity, Fitzpatrick skin type, and hirsutism: A retrospective cross-sectional study of women with polycystic ovarian syndrome.
Afifi L; Saeed L; Pasch LA; Huddleston HG; Cedars MI; Zane LT; Shinkai K
Int J Womens Dermatol; 2017 Mar; 3(1):37-43. PubMed ID: 28492053
[TBL] [Abstract][Full Text] [Related]
50. Hirsutism, Normal Androgens and Diagnosis of PCOS.
Spritzer PM; Marchesan LB; Santos BR; Fighera TM
Diagnostics (Basel); 2022 Aug; 12(8):. PubMed ID: 36010272
[TBL] [Abstract][Full Text] [Related]
51. Hirsutism and oligomenorrhea are appropriate screening criteria for polycystic ovary syndrome in adolescents.
Villarroel C; López P; Merino PM; Iñiguez G; Sir-Petermann T; Codner E
Gynecol Endocrinol; 2015; 31(8):625-9. PubMed ID: 26190534
[TBL] [Abstract][Full Text] [Related]
52. Leptin concentrations in hirsute women with polycystic ovary syndrome or idiopathic hirsutism: influence on LH and relationship with hormonal, metabolic, and anthropometric measurements.
Spritzer PM; Poy M; Wiltgen D; Mylius LS; Capp E
Hum Reprod; 2001 Jul; 16(7):1340-6. PubMed ID: 11425810
[TBL] [Abstract][Full Text] [Related]
53. Effectiveness of different diagnostic methods for assessment of hyperandrogenism in young women with hirsutism.
Chanukvadze D; Kristesashvili J
Georgian Med News; 2011 Nov; 11(200):25-9. PubMed ID: 22201076
[TBL] [Abstract][Full Text] [Related]
54. High prevalence of the polycystic ovary syndrome and hirsutism in women with type 1 diabetes mellitus.
Escobar-Morreale HF; Roldán B; Barrio R; Alonso M; Sancho J; de la Calle H; García-Robles R
J Clin Endocrinol Metab; 2000 Nov; 85(11):4182-7. PubMed ID: 11095451
[TBL] [Abstract][Full Text] [Related]
55. Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Müllerian hormone concentrations aggregate with the markers of hyperandrogenism.
Dewailly D; Pigny P; Soudan B; Catteau-Jonard S; Decanter C; Poncelet E; Duhamel A
J Clin Endocrinol Metab; 2010 Sep; 95(9):4399-405. PubMed ID: 20610596
[TBL] [Abstract][Full Text] [Related]
56. Metastin levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome.
Yilmaz SA; Kerimoglu OS; Pekin AT; Incesu F; Dogan NU; Celik C; Unlu A
Eur J Obstet Gynecol Reprod Biol; 2014 Sep; 180():56-60. PubMed ID: 25020276
[TBL] [Abstract][Full Text] [Related]
57. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives.
Mastorakos G; Koliopoulos C; Creatsas G
Fertil Steril; 2002 May; 77(5):919-27. PubMed ID: 12009344
[TBL] [Abstract][Full Text] [Related]
58. Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS).
Kumar A; Woods KS; Bartolucci AA; Azziz R
Clin Endocrinol (Oxf); 2005 Jun; 62(6):644-9. PubMed ID: 15943823
[TBL] [Abstract][Full Text] [Related]
59. Clinical observations and hormone screenings of patients with non-standard hypertrophy of the adrenal cortex.
Franik G; Skałba P
Endokrynol Pol; 2011; 62(3):230-7. PubMed ID: 21717405
[TBL] [Abstract][Full Text] [Related]
60. Assessing new terminal body and facial hair growth during pregnancy: toward developing a simplified visual scoring system for hirsutism.
Yang Y; Han Y; Wang W; Du T; Li Y; Zhang J; Yang D; Zhao X
Fertil Steril; 2016 Feb; 105(2):494-500. PubMed ID: 26616440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
